This study is looking at how a drug called CST-3056, given as an oral solution, affects people with neurogenic orthostatic hypotension (nOH). nOH is a condition where your blood pressure drops significantly when you stand up, often due to Parkinson's disease or pure autonomic failure. Researchers want to see if CST-3056 can improve symptoms and signs of nOH. You might be able to join if you are between 18 and 85 years old and have been diagnosed with symptomatic nOH. The main way they will measure success is by checking changes in your standing systolic blood pressure (the top number in a blood pressure reading) over several hours after taking the drug. The study is currently unclear about its recruitment status and plans to enroll 12 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It is a single-blind, dose-ranging study, meaning you won't know if you're getting CST-3056 or a placebo (an inactive substance), but the researchers will.

What's involved

You would take single oral doses of CST-3056 or placebo once daily for five days. You may need to stop certain medications for at least one day before screening and before starting the study drug.

Compensation

Not stated in the trial record.

Follow-up

Between 3-7 days after leaving the in-patient stay, you will be contacted by phone to check on your health status.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.